Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells $403,620.84 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 7,308 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $403,620.84. Following the completion of the transaction, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ian Mortimer also recently made the following trade(s):

• On Tuesday, March 10th, Ian Mortimer sold 11,269 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total value of $677,379.59.
• On Monday, March 9th, Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00.

Xenon Pharmaceuticals Stock Down 4.6%

Shares of NASDAQ XENE traded down $2.67 during trading hours on Friday, reaching $55.23. 3,849,961 shares of the stock traded hands, compared to its average volume of 1,923,723. The company has a market capitalization of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $63.95. The company’s 50-day simple moving average is $43.71 and its two-hundred day simple moving average is $41.92.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the prior year, the company earned ($0.84) EPS. As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on XENE. Robert W. Baird upped their price objective on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday. Morgan Stanley set a $97.00 target price on shares of Xenon Pharmaceuticals in a report on Monday. Wolfe Research began coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $71.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in XENE. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $33,000. Blue Trust Inc. boosted its position in Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the last quarter. Danske Bank A S purchased a new position in Xenon Pharmaceuticals in the third quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $43,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.